

The science behind haemophilia gene therapy: where are we in 2022?



Exploring the latest insights and building on current understanding of the complex science of gene therapy

Agenda

Co-chairs: Gili Kenet (Israel), Damien Simoneau (Pfizer)

Time	Title	Presenter
18:00 CET	Welcome and introduction	Gili Kenet (Co-chair) Professor and Paediatric Haematologist at the Haematology Department, Sackler Medical School, Tel Aviv University, Israel
18:06 CET	Response to experimental therapy: variability and long-term outcomes	John Rasko Professor and Head of Department, Cell & Molecular Therapies, Royal Prince Alfred Hospital, New South Wales, Australia
18:18 CET	Importance of the interpretation of biological efficacy outcomes: assay discrepancies and their implications	Annette Bowyer Section Lead for Haemophilia Assays, Department of Coagulation at Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK
18:30 CET	Identifying the candidates for haemophilia gene therapy trials: key considerations in patient selection	Andreas Tiede Professor and Head of the Haemophilia Care Centre and Haemostasis/Thrombosis Unit, Hannover Medical School, Hannover, Germany
18:42 CET	Panel discussion	All - moderated by the Co-chairs
18:57 CET	Meeting summary and close	Damien Simoneau Global Senior Medical Director Haemophilia, Pfizer